retatrutide eli lilly press release 2024 2025 Lilly's triple agonist hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Novo Duopoly Lilly's triple-acting obesity drug hits

PHD, Prolyl-hydroxylases

Autophagy activity is up-regulated in adipose tissue of obese individuals and modulates proinflammatory cytokine expression

Targeting metabolic vulnerabilities in specific macrophage subsets, such as limiting ferroportin-mediated iron export in M2 TAMs or enhancing ACSL4-dependent lipid peroxidation in inflammatory TAMs, may shift the TME toward a ferroptosis-permissive state

As further research and clinical trials unfold, these drugs hold promise for a healthier future for individuals struggling with obesity and related conditions

Conventional Therapies : Traditional medical treatments like physical therapy, rehabilitation exercises, and anti-inflammatory medications also serve as alternatives, especially considering the uncertainty and lack of human data surrounding peptide therapies2

And then there are the links here